Floatz logo

Sorafenib

Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter

National Cancer Institute (NCI)Small moleculePhase 2Dormant
B
57/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
42/ 100
Competitive Position
95/ 100

Competitive context

18 Active assets in the Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter cohort.

Asset / SponsorPhaseRating
Carboplatin
Cardiff University
Phase 3BBB
CIS-DIAMMINEDICHLOROPLATINUM II
Nagoya University
Phase 3BBB
VINBLASTINE
University of Southern California
Phase 3BBB
Inno-206
University of Southern California
Phase 3BBB
FILGRASTIM
Tulane University Health Sciences Center
Phase 2BBB

View all 50 →

Same molecule, other indications

Sorafenib is also rated in:

renal cell carcinomaDormant
BBB
Indicative ·
79 / 100
View asset →
SorafenibDormant
BBB
Indicative ·
75 / 100
View asset →
portal vein thrombosisDormant
BBB
Indicative ·
74 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →